Written Question·Department of Health and Social Care·UIN 74757

Thyroid Cancer: Liothyronine

Tabled: 3 September 2025
Answered: 9 October 2025

Question

James Naish

LabourRushcliffe

To ask the Secretary of State for Health and Social Care, when NICE last reviewed its guidance on the (a) availability and (b) prescribing of T3 for the treatment of thyroid cancer; and whether he has plans to improve access to T3 for patients where it is

Answer

Dr Zubir Ahmed
The National Institute for Health and Care Excellence (NICE) has not made any recommendations on the use of liothyronine in the treatment of thyroid cancer. NICE published a guideline on the assessment and management of thyroid cancer in December 2022. Th...

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 74757) →

Thyroid Cancer: Liothyronine — Written Question | TrustPolitics